Type to search

Transine Therapeutics Announces Final Closing of its Seed Round at £13.7m to Accelerate its Platform and Portfolio Development | Pharmtech Focus
Transine Therapeutics Appoints Industry Veteran Jan Thirkettle Ph.D. as CEO | Pharmtech Focus